Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3776MR)

This product GTTS-WQ3776MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3776MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12163MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MORAb-009
GTTS-WQ766MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AB0024
GTTS-WQ1418MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ3624MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ12519MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ404MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ10045MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ6388MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW